Cochlear Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Cochlear de 7.7% y 4.2% por año respectivamente. Se prevé que el BPA crezca en un 7.4% al año. Se espera que la rentabilidad financiera sea de 18.2% en 3 años.
Información clave
7.7%
Tasa de crecimiento de los beneficios
7.39%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 13.0% |
| Tasa de crecimiento de los ingresos | 4.2% |
| Rentabilidad financiera futura | 18.21% |
| Cobertura de analistas | Good |
| Última actualización | 16 Jul 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jul 16
COH: Profit Downgrade And Softer Implant Demand Will Pressure Earnings Expectations
The analyst fair value estimate for Cochlear has increased from A$95 to A$100, reflecting updated assumptions related to discount rates, modest adjustments to long-term revenue growth and profit margins, and a slightly higher future P/E multiple cited by analysts in recent research. Analyst Commentary Recent research on Cochlear points to a more mixed setup, with some analysts highlighting risks that could limit upside from current levels.Actualización de narrativa • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Artículo de análisis • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...
Actualización de narrativa • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Actualización de narrativa • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Actualización de narrativa • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
Nueva narrativa • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Actualización de narrativa • Apr 21
COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments
The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.Actualización de narrativa • Apr 04
COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside
Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.Actualización de narrativa • Mar 21
COH: VA Access Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.Actualización de narrativa • Mar 06
COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential
Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.Nueva narrativa • Mar 01
Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability
Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Feb 20
COH: Reset Expectations And Product Adoption Will Support Future Upside Potential
Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.Artículo de análisis • Feb 16
Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...Artículo de análisis • Feb 15
Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%
Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Nueva narrativa • Feb 13
Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion
Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Artículo de análisis • Feb 06
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Actualización de narrativa • Feb 05
COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential
Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.Artículo de análisis • Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Artículo de análisis • Nov 18
Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...Artículo de análisis • Oct 14
Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Sep 28
We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Actualización de narrativa • Sep 19
Aging Population Will Spur Cochlear Implant Adoption Worldwide
Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.Artículo de análisis • Aug 26
Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...Actualización de narrativa • Aug 19
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.
Nueva narrativa • Feb 23
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2029 | 2,678 | 406 | 409 | 491 | 3 |
| 6/30/2028 | 2,565 | 375 | 360 | 476 | 15 |
| 6/30/2027 | 2,415 | 322 | 324 | 434 | 16 |
| 6/30/2026 | 2,322 | 234 | 237 | 382 | 16 |
| 12/31/2025 | 2,339 | 345 | 166 | 265 | N/A |
| 9/30/2025 | 2,341 | 367 | 150 | 251 | N/A |
| 6/30/2025 | 2,343 | 389 | 135 | 238 | N/A |
| 3/31/2025 | 2,326 | 380 | 193 | 290 | N/A |
| 12/31/2024 | 2,309 | 371 | 251 | 342 | N/A |
| 9/30/2024 | 2,272 | 364 | 275 | 365 | N/A |
| 6/30/2024 | 2,236 | 357 | 299 | 389 | N/A |
| 3/31/2024 | 2,193 | 354 | 317 | 410 | N/A |
| 12/31/2023 | 2,149 | 350 | 335 | 430 | N/A |
| 9/30/2023 | 2,043 | 326 | 301 | 396 | N/A |
| 6/30/2023 | 1,936 | 301 | 267 | 362 | N/A |
| 3/31/2023 | 1,824 | 281 | 263 | 352 | N/A |
| 12/31/2022 | 1,713 | 261 | 259 | 341 | N/A |
| 9/30/2022 | 1,681 | 275 | 279 | 359 | N/A |
| 6/30/2022 | 1,648 | 289 | 299 | 377 | N/A |
| 3/31/2022 | 1,612 | 273 | 266 | 340 | N/A |
| 12/31/2021 | 1,575 | 257 | 233 | 304 | N/A |
| 9/30/2021 | 1,536 | 291 | 216 | 285 | N/A |
| 6/30/2021 | 1,498 | 324 | 199 | 265 | N/A |
| 3/31/2021 | 1,403 | 82 | -52 | 34 | N/A |
| 12/31/2020 | 1,308 | -160 | -302 | -198 | N/A |
| 9/30/2020 | 1,314 | -199 | -295 | -178 | N/A |
| 6/30/2020 | 1,321 | -238 | -288 | -158 | N/A |
| 3/31/2020 | 1,400 | 34 | -80 | 50 | N/A |
| 12/31/2019 | 1,479 | 306 | 128 | 259 | N/A |
| 9/30/2019 | 1,453 | 291 | N/A | 277 | N/A |
| 6/30/2019 | 1,427 | 277 | N/A | 296 | N/A |
| 3/31/2019 | 1,422 | 270 | N/A | 313 | N/A |
| 12/31/2018 | 1,418 | 264 | N/A | 330 | N/A |
| 9/30/2018 | 1,391 | 255 | N/A | 294 | N/A |
| 6/30/2018 | 1,364 | 246 | N/A | 258 | N/A |
| 3/31/2018 | 1,329 | 234 | N/A | 254 | N/A |
| 12/31/2017 | 1,294 | 223 | N/A | 250 | N/A |
| 9/30/2017 | 1,274 | 223 | N/A | 255 | N/A |
| 6/30/2017 | 1,254 | 224 | N/A | 260 | N/A |
| 3/31/2017 | 1,218 | 215 | N/A | 237 | N/A |
| 12/31/2016 | 1,182 | 206 | N/A | 214 | N/A |
| 9/30/2016 | 1,156 | 198 | N/A | 199 | N/A |
| 6/30/2016 | 1,131 | 189 | N/A | 185 | N/A |
| 3/31/2016 | 1,088 | 179 | N/A | 179 | N/A |
| 12/31/2015 | 1,045 | 168 | N/A | 172 | N/A |
| 9/30/2015 | 986 | 157 | N/A | 181 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (7.7% al año) de COH es superior a la tasa de ahorro (3.6%).
Beneficios vs. Mercado: Se prevé que los beneficios (7.7% al año) de COH crezcan menos que el mercado Australian (11.5% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de COH crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (4.2% al año) de COH crezcan más despacio que el mercado de Australian (5.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 4.2% al año) de COH crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de COH sea baja dentro de 3 años (18.2%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/17 23:53 |
| Precio de las acciones al final del día | 2026/07/17 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cochlear Limited está cubierta por 26 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Stuart Roberts | Bell Potter |
| Elisabeth Decou Clive | Bernstein |